Concepedia

Daniil Stroyakovsky

DS

4

Publications

168

Citations

4

H-Index

2010

Active since

Affiliations

Moscow City Oncology Hospital №62(Current)

BIOCAD (Russia)

Perm Regional Oncology Center

Volgograd Regional Clinical Oncology Center

Russian Cancer Research Center NN Blokhin

Daniil Stroyakovsky is an author at Moscow City Oncology Hospital №62 specializing in medicine, oncology, and pharmacology.

Top concepts

MedicineOncologyPharmacologyCancer TherapyPharmacotherapyClinical TrialsRadiation OncologyClinical PharmacologyHealthImmunology

Publications per year

2010–2014

4

Publications

4

A Dose Finding Study of Weekly and Every-3-Week nab-Paclitaxel Followed by Carboplatin as First-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer

Mark A. Socinski, G. Manikhas, Daniil Stroyakovsky et al. · Journal of Thoracic Oncology · 2010 · 75 citations · Full text

First-line Therapy, Oncology, Pharmacology +5

COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF<sup>V600E/K </sup>mutation-positive cutaneous melanoma

Georgina V. Long, Daniil Stroyakovsky, Helen Gogas et al. · Journal of Clinical Oncology · 2014 · 69 citations

First-line Therapy, Immunology, Pharmacotherapy +16

Pharmacokinetics and safety of BCD-021, bevacizumab biosimilar candidate, compared to Avastin in patients.

Sergey Orlov, Olga Burdaeva, Marina P. Nechaeva et al. · Journal of Clinical Oncology · 2014 · 13 citations

Pharmacotherapy, Bevacizumab Biosimilar Candidate, Pre-clinical Pharmacology +16

Pharmacokinetics and safety of BCD-022, trastuzumab biosimilar candidate, compared to Herceptin in patients.

E. Ignatova, Olga Burdaeva, Marina P. Nechaeva et al. · Journal of Clinical Oncology · 2014 · 11 citations

Single Bcd-022, Therapeutic Drug Monitoring, Translational Medicine +14

Rows per page

1–4 of 4